CAPR CAPRICOR THERAPEUTICS, INC. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$26.71

Period return

-1.85 (-6.48%)

Volume

574.8K

2026-06-05O $27.88 H $27.95 L $26.56 C $26.71MA5 $27.63MA20 $29.04MA60 $31.2MA120 $28.66

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 13.LowBUY24 days ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 03. 14.LowBUY3 months ago
B. Riley Securities: Buy
US analyst rating / recommendation change.
2026. 03. 14.LowBUY3 months ago
Piper Sandler: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $54.11 · 9 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Sector: Healthcare
Industry: Biotechnology

2026. 03. 13.LowBUY3 months ago

HC Wainwright & Co.: Buy